Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections

Trial Profile

Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Posaconazole (Primary)
  • Indications Mycoses
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 May 2016 Status changed from active, no longer recruiting to completed.
    • 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
    • 04 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top